NCT07882212Not yet recruiting
GRACE-DE: Prospective Multicenter Real-world Gastric Cancer Patients Starting AZ-developed and Approved Drugs in Germany (Umbrella Study)
Prospective, Observational, Multicenter, and Multicohort Study of Patients With Gastric Cancer Initiating AstraZeneca-developed and Approved Drugs in Germany GastRic CAnCEr Real-World Evidence Germany (Umbrella Study)
Source: ClinicalTrials.gov · Last updated 20 Oct 2026
Brief summary (registry, in English)
This is a prospective, non-interventional, observational, multicentre study evaluating the real-world effectiveness and safety of AstraZeneca-developed and approved medicines used to treat gastric and/or oesophageal cancers in Germany. The study is designed as an umbrella study comprising several drug- and indication-specific modules. The present description covers Module A, which evaluates durvalumab used perioperatively in combination with FLOT chemotherapy (D-FLOT), followed by adjuvant durvalumab monotherapy in adults with resectable gastric or gastro-oesophageal junction adenocarcinoma in routine clinical practice in Germany.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 12 Oct 2026
- Start date
- 31 Oct 2026
- Primary completion date
- 30 Sept 2031
- Lead sponsor
- AstraZeneca
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07882212
What you commit to
- Study type: Observational
- Planned participants: 300
- From 31 Oct 2026 to the primary completion date, 30 Sept 2031
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Current active and already planned participation in an interventional clinical trial for stomach and/or esophageal cancer.
Who the study is looking for
- Age ≥18 years at the time of enrolment
- Patient is able to read and understand either German or English
- Histologically or cytologically proven resectable adenocarcinoma of the stomach or of the gastroesophageal junction (GC/GEJC) and decision to start perioperative treatment with durvalumab and FLOT chemotherapy (D-FLOT), followed by adjuvant durvalumab as monotherapy, according to its marketing authorization (SmPC). Inclusion can also take place after the 1st dose of perioperative D-FLOT but no later than 4 weeks after treatment initiation. (Modul A)
- Treatment decision was made independently from study participation
- Provision of signed and dated written informed consent to participate in the study
Age in the registry: 18 years to 130 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.